Adalimumab Safety and Effectiveness in Children With Crohn's Disease
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study tracks how well and how safely a medicine called adalimumab works in children ages 6–17 with moderate-to-severe Crohn's disease (a condition causing inflammation in the digestive tract). Your child's doctor has already decided adalimumab is appropriate for them, and this study simply collects information about how they respond to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 6 and 17 years old
- Your child has been diagnosed with moderate-to-severe active Crohn's disease
- Your child's doctor has prescribed adalimumab injection for them and believes it is appropriate
- Your child has not received any live vaccines in the 3 months before starting adalimumab
- Your child is not currently enrolled in another clinical trial
- Both you and your child (if old enough) must sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This trial tests a medication called adalimumab (a biologic drug that reduces inflammation) in children with severe plaque psoriasis—a skin condition causing thick, scaly patches. The study aims to see if this injection can help children whose skin hasn't improved with creams, light therapy, or other treatments.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
This study tests a combination of two drugs, infliximab and azathioprine, to see if it works better than either drug alone for children with moderate to severe Crohn's disease. The trial is for children who have not used these drugs before.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Hear when a new Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.